tivozanib (Fotivda)

following a full submission assessed under the end of life process:

tivozanib (Fotivda®) is accepted for restricted use within NHSScotland.

Indication under review: the first-line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are vascular endothelial growth factor receptor and mammalian target of rapamycin pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced renal cell carcinoma (RCC).

SMC restriction: to first-line treatment of advanced RCC.

In a phase III, open-label, randomised, controlled study tivozanib increased progression free survival when compared with a multi-kinase inhibitor in patients with advanced RCC.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of tivozanib. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting